Evidence map›Paper›PMID 24326350›Full record

ReviewPhysiological genomics2014

MicroRNAs in normal and psoriatic skin.

Jing Xia, Weixiong Zhang

Abstract readReview
In one paragraph

Review in Physiological genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Non-viral based miR delivery and recent developments.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2018
    Review
  11. Review
  12. Article
  13. Article
  14. Role of MicroRNAs in NAFLD/NASH.Digestive diseases and sciences · 2016
    Review
  15. MicroRNAs as regulatory elements in psoriasis.Open medicine (Warsaw, Poland) · 2016
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Jing XiaInstitute for Systems Biology, Jianghan University, Wuhan, Hubei, China;
Weixiong Zhang
Washington University in St. Louis · US

Funding

A NOVEL CO-EXPRESSION NETWORK APPROACH THAT IS ROBUST TO GENETIC HETEROGENEITY ANR01GM100364 · NIGMS · WASHINGTON UNIVERSITY · PI ZHANG, WEIXIONG · 2012 to 2015
$1.2M
Systems Biology of PsoriasisRC1AR058681 · NIAMS · WASHINGTON UNIVERSITY · PI BOWCOCK, ANNE MARY, ZHANG, WEIXIONG · 2009 to 2010
$998k
NIAMS NIH HHS RC1AR-058681NIGMS NIH HHS R01 GM100364NIGMS NIH HHS R01GM-100364
6 · The paper itself

Abstract

Psoriasis is a chronic and common human skin disorder currently with no cure. Psoriatic skin displays inflammatory, raised, and scaly lesions with widely aberrant gene expression. Recent studies have revealed critical roles that microRNAs play as a class of posttranscriptional gene regulator in skin development and skin diseases. A substantial number of novel microRNAs have been identified in skin, and much has been learned about the dysregulated expression and functional roles of microRNAs in psoriasis, as well as the robustness and plasticity of microRNA-mediated gene expression regulation. Here we review recent progresses in discovery, profiling, and characterization of microRNAs in human psoriatic skin, discuss insights to their biological functions, and share our view on remaining challenges to be addressed.

Indexed as

Models, BiologicalGene Expression RegulationHumansMicroRNAsPsoriasisSkinMicroRNAsendogenous siRNAmicroRNApsoriasisskin development

Identifiers

PMID24326350
PMCPMC3921347
OpenAlexW2161283642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.